This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Pulmonary Tuberculosis
and you are
between 18 and 45
years old
Phase
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

The purpose of this study is to determine the safety, tolerability, and immunogenicity in healthy adult subjects of an investigational vaccine being developed for the prevention of pulmonary tuberculosis. The vaccine, identified as ID93 + GLA-SE, consists of the recombinant four-antigen Mycobacterium tuberculosis recombinant protein ID93 together with the adjuvant GLA-SE.

Provided treatments

  • Biological: ID93 + GLA-SE
  • Biological: ID93 alone
Tris trial is registered with FDA with number: NCT01599897. The sponsor of the trial is IDRI and it is looking for 60 volunteers for the current phase.
Official trial title:
A Phase 1, Randomized, Dose-escalation Study to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine at Two Dose Levels of the ID93 Antigen and the GLA-SE Adjuvant in Healthy Adults